From a Parkinson's disease expert: Rasagiline and the Future of Therapy
2007
Rasagiline and the Future of Therapy
Commentary
Author Information
Author(s): Lakhan Shaheen E
Primary Institution: Global Neuroscience Initiative Foundation
Conclusion
Rasagiline is effective in treating early-stage Parkinson's disease and may have neuroprotective properties.
Supporting Evidence
- Rasagiline gained UK- and EU-marketing authorization in 2005 and US FDA approval in 2006.
- Rasagiline is effective in monotherapy in the early stage of Parkinson's disease.
- Rasagiline may cause neuroprotection by reducing the metabolism of dopamine.
Takeaway
Rasagiline is a medicine that helps people with Parkinson's disease feel better and may also protect their brain.
Methodology
The commentary discusses the development and effects of rasagiline based on clinical research and pharmacological studies.
Potential Biases
There may be risks of bias due to the author's involvement in the drug's development.
Limitations
The commentary does not provide specific limitations of the studies discussed.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website